Archives: Agenda

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within oncology clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice

1. Deep dive workshop on site selection

Hosted by Faraz Siddiq, Assistant General Counsel – EDD, Memorial Sloan Kettering Cancer Center

2. ClinOps challenges in a digital age

Hosted by George Naumov, Chief Operating Officer, RS Oncology

3. How to strategically plan and curb risk as a small biotech

4. AI in oncology clinical trials

This session will explore recent findings from the Tufts Center for the Study of Drug Development (CSDD) on the current landscape of decentralized clinical trial (DCT) solutions, addressing key questions including:

• How are DCT solutions being funded, and to what extent?
• How are resources being deployed for DCT implementation across research site types?
• Which DCT solutions are most heavily funded and supported?
• What are participant and site perspectives on direct-to-participant investigational products – what’s working and what’s challenging?

• Start with what matters but allow imagination in how you define “what matters”
• Design for a moving target by embracing uncertainty as a creative tool, not a risk to avoid
• Execute with discipline but treat operational constraints as a spark for innovation
• Making the right choices at the right Time: Look to employ clear, patient-anchored frameworks to advance, pause, or pivot programs at critical inflection points
• Keep patients at the center because nothing generates creativity like unmet human

• Synthetic populations and AI-simulated control arms are already reducing reliance on traditional randomization
• Real-time, adaptive approval models could replace rigid phase boundaries
• Continuous post-market learning may become as important as pre-market proof
• Decision-making authority shifts as AI accelerates evidence generation beyond human-paced review cycles

• Integrating patient insights early in protocol and endpoint design
• Partnering with advocacy organizations to reach diverse and underrepresented populations
• Aligning patient engagement strategies with regulatory and ethical expectations
• Measuring the impact of patient-centric approaches on trial outcomes